

## SUBJECT INDEX TO VOLUME 6

17-AAG .....	1209	tau pathology in .....	580
clinical trials of .....	1209	tau phosphatases in .....	589
pharmacodynamic studies of .....	1210	tau protein in .....	579
ABX-EGF .....	1699	tau therapeutic strategies for .....	579
Acetylcholinesterase .....	57	tau transgenic mice for .....	613
covalent bonding effects of .....	65	treatment of .....	579
dynamic properties/effects of .....	61	treatment of cognitive dysfunction in .....	553
function of .....	58	white matter changes in .....	631
inhibition of .....	58	4-Aminoquinoline antimalarial drugs .....	479
non-covalent inhibition of .....	63	mechanism of action of .....	479
structure of .....	58	medicinal chemistry of .....	479
Adenosine A <sub>1</sub> receptor .....	1376	structure activity relationship (SAR) studies of .....	484
Adenosine receptor ligands .....	1375	Amodiaquine series .....	494
as anti-inflammatory drug .....	1375	SAR in .....	494
development of .....	1375	AMPA receptor .....	832
indirect mechanisms of .....	1391	studies on .....	832
ADME .....	1593	Amphotericin B .....	542
development of classification models for .....	1594	mechanism of action of .....	543
Alkyl guanidines .....	763	resistance to .....	543
Allopurinol .....	544	Amyloid-beta derived diffusible ligands (ADDLs) .....	597
Alzheimer's disease .....	553,579,597,609,629	biological characteristics of .....	598
acetylcholinesterase inhibitors for .....	554	functional activity of .....	599
amyloid hypothesis for pathophysiology of .....	610	<i>in vivo</i> .....	600
amyloid imaging in .....	633	methods for therapeutic intervention .....	601
amyloid plaque imaging agents in .....	634	preparation/isolation of .....	598
anti-NGF (nerve growth factor) expressing AD11 mice for .....	616	role in Alzheimer's disease .....	597
APP/presenilin transgenic mice in .....	612	Androgen receptor (AR) .....	245
blood flow in .....	634	activity of endogenous ligands of .....	246
brain glucose metabolism in .....	634	medicinal chemistry of .....	245
CaMKII in .....	588	pharmacology of .....	245
cannabinoid receptor ligands for .....	558	therapeutic potential of .....	245
cdk-5 in .....	583	Ankylosing spondylitis (AS) .....	1709
diffusion tensor MRI in .....	631	adalimumab in .....	1710
genetically modified mice models for .....	609	etanercept in .....	1710
glycogen synthase kinase (GSK)-3 in .....	584	infliximab in .....	1709
histamine-3 receptor antagonists for .....	559	Anti-cancer enzyme inhibitors .....	472
5-HT <sub>1A</sub> receptor antagonists for .....	560	Anti-cancer therapy .....	1687
5-HT <sub>6</sub> receptor antagonists for .....	561	by conjugated antibodies .....	1688
magnetic resonance spectroscopy in .....	632	immune mediated .....	1688
mechanisms of tau-mediated toxicity in .....	582	molecular engineering techniques for .....	1689
mice models for .....	612	timing/schedule of trastuzumab in .....	1696
microtubule affinity regulating kinase (MARK) in .....	588	Anti-CD33 .....	1667
mitogen activated protein kinases (MAPK) in .....	587	pharmacokinetics/dosage of .....	1667
muscarinic M1 receptor agonists for .....	555	toxicity of .....	1667
muscarinic M2 receptor antagonists for .....	556	Antiestrogens .....	217
nicotine receptor agonists for .....	557	development of .....	217
NMDA receptor antagonists for .....	554	raloxifene as .....	218
palliative therapies for .....	553	tamoxifen as .....	218
phosphodiesterase-4 inhibitors for .....	558	Antigenic/immunogenic conjugates .....	1715
role of MRI .....	629	artificial carriers for .....	1716
role of PET/SPECT in .....	629,634	protein carriers for .....	1715
structural MRI in .....	629	sequential oligopeptide carriers SOC <sub>n</sub> for .....	1720
tau kinases in .....	583	strategy for constructing .....	1715

Anti-inflammatory drug development .....	165	Arylamine <i>N</i> -acetyltransferases (NATs) .....	1641
targeting secretory pathway for .....	165	enzyme reaction mechanism of .....	1645
Anti-inflammatory effect .....	1375	mechanism of .....	1641
of A <sub>2B</sub> receptor ligands .....	1382	structure of .....	1641
of adenosine A <sub>1</sub> receptor agonists .....	1376	structure-activity relationships of .....	1646
of adenosine A <sub>2A</sub> receptor .....	1378	structures of prokarotic type .....	1642
of adenosine A <sub>3</sub> receptor ligands .....	1386	Asthma .....	393
Antileishmanial modulators .....	539	serine proteases in .....	397
design of .....	539	targeting chymase in .....	396
therapeutic target identification of .....	539	targeting leukocyte elastase in .....	397
Antimonials .....	540	targeting serine proteases in .....	393
amphotericin B for .....	543	trypase in .....	393
mechanism of action of .....	540	Atherosclerosis .....	93
paromomycin for .....	544	as inflammatory disorder .....	93
resistance to .....	541	effect of cholesterol .....	93
sitamaquine for .....	544	ATP/GTP-binding pockets .....	1140
Antisense-based therapeutics .....	1748	Atypical NR2B antagonists .....	701
Anti-targets .....	1136	structural motifs of .....	701
engineering selectivity against .....	1139	Autoimmune diseases .....	1707
selectivity of .....	1138	adalimumab in .....	1709
Antiviral/anti-tumor agents .....	1499	anti-TNF- antibody therapies in .....	1707
6',6'-difluorinated nucleoside analogues as .....	1520	etanercept in .....	1709
2'-fluorinated nucleosides as .....	1499	infliximab in .....	1708
3'-modified fluoro nucleosides as .....	1514	lenercept in .....	1709
nucleosides containing fluorocyclopropane .....	1523	AVP-13358 .....	173
moiety as .....	1523	6-Azasteroids .....	411
Appetite suppressants .....	1847	discovery of .....	411
Aromatic fluorine .....	1473	medicinal chemistry of .....	411
cation-II interactions of .....	1475	pharmacokinetic studies of .....	412
effects of .....	1473	Benzoquinone ansamycins .....	1164
face-to-face arene-arene interactions of .....	1476	Bevacizumab .....	1697
gas phase/solution phase interactions of .....	1475	in breast cancer .....	1698
interactions of C-F dipole .....	1478	in colorectal cancer .....	1698
T-shaped arene-arene interactions of .....	1477	in non small cell lung cancer (NSCLC) .....	1698
<i>Artemisia annua</i> .....	511	in renal cancer .....	1698
artemether/artether from .....	516	Bisquinolines .....	486
artesanate from .....	514	BK <sub>CA</sub> channels .....	1026
cultivation/harvesting of .....	511	direct stimulation or inhibition of .....	1026
dihydroartemisinin from .....	512	Bortezomib .....	1673
extraction of artemisinin from .....	511	Bradykinin receptor ligands .....	1353
Artemisinin .....	509,1532	development of .....	1353
11-azaartemisinins from .....	518	Breast cancer .....	181
biosynthesis of .....	509	acolbifene in .....	187
derivatives from .....	518	anastrozole in .....	189
derivatives of .....	509	antiestrogens in .....	191
extraction of .....	509	aromatase inhibitor resistance in .....	194
fluorinated analogues of .....	1532	aromatase inhibitors in .....	187
fluorinated artemisinins from .....	519	arzoxifene in .....	187
from <i>Artemisia annua</i> .....	509	balance of coactivators/corepressors in .....	195
medicinal chemistry of .....	509	bazedoxifene in .....	187
requirements of .....	509	droloxifene in .....	186
stereochemistry of .....	509	EM-800 in .....	187
Artificial carriers .....	1715	ER -vs. ER -specific ligands in .....	183
as human vaccine candidates .....	1727	estrogen receptor targeted therapies for .....	184
modified sequential oligopeptide based .....	1727		

estrogen receptor in .....	182	CCR3 non-peptide ligands .....	1327
estrogen receptor in .....	183	CCR4 .....	1335
exemestane in .....	190	as target for disease intervention .....	1336
formestane in .....	190	role in immunomodulation .....	1335
fulvestrant in .....	191	CCR4 antagonists .....	1337
GW5638/GW7604 in .....	186	aryl sulfonamides as .....	1337
idoxifene in .....	187	lactams as .....	1341
lasofoxifene in .....	187	small molecule based .....	1337
letrozole in .....	189	substituted amino heterocycles as .....	1337
long term phase II SERM resistance in .....	193	thiazolidinones as .....	1340
mechanisms of endocrine-based therapy		CCR5 non-peptide ligands .....	1322
resistance in .....	194	CD38 regulatory T-cells .....	1764
non-steroidal aromatase inhibitors in .....	189	CD4 <sup>+</sup> /CD25 <sup>+</sup> cells .....	1764
plasma membrane ER in .....	195	in disease .....	1764
raloxifene in .....	185	Central nervous system .....	979
Ru 58668 in .....	192	co-existence of GABA/Glu transporters in .....	979
short term phase I SERM resistance in .....	193	morphological evidence for GABA/glutamate	
steroidal aromatase inhibitors in .....	190	heterotransporters in .....	984
tamoxifen in .....	184	Cetuximab .....	1691
TAS-108 in .....	192	bond study of .....	1692
toremifene in .....	186	clinical data-phase I trials of .....	1692
ZK-703/ZK-253 in .....	191	phase II trials of .....	1692
Brefeldin A .....	173	pre-clinical data of .....	1691
C-20 cyclopropyl vitamin D <sub>3</sub> analogs .....	1289	Chemokine receptors .....	1328
genomic biological/metabolic properties of .....	1291	antagonists for .....	1321
immunomodulatory activity of .....	1292	non-peptide ligands for .....	1328
synthesis of .....	1289	Chloroquine series .....	484
Calcium-activated potassium channel .....	1025	structure activity relationships in .....	484
large-conductance type .....	1025	Chronic inflammation .....	103
pharmacological roles of .....	1025	with pathway selective estrogen receptor	
Calcium ion .....	962	ligands .....	103
induced signaling in trophic effect of EAAs .....	962	Chymase .....	395
Campath-1H .....	1664	CNS drugs .....	1457
in leukemia .....	1664	compounds targeting NMDA receptors as .....	1459
mechanisms of action of .....	1664	fluorine in discovery of .....	1462
Camptothecin .....	1530	Cocaine .....	1977
fluorinated analogues of .....	1530	pharmacotherapy in humans .....	1977
Cancer .....	203,1129,1163,1193,1297	Competitive glutamate site antagonists .....	756
doxorubicin/epirubicin inhibiting bladder cell		Competitive Gly/NMDA receptor antagonists .....	809
line proliferation of .....	1298	amino acid derivatives as .....	818
estrogen-related receptors as targets in .....	203	2-carboxytetrahydroquinolines as .....	811
multi-nodal targeting in .....	1163	1,2-dihydropyridazino[4,5-b]quinolines as .....	816
synergistic effect of calcitriol .....	1298	4-hydroxy-quinolin-2(1H)-ones as .....	815
targeting of .....	1129	indeno[1,2-B]pyrazin-2,3-dione derivatives as .....	817
VDR agonists for .....	1298	indole-2-carboxylic acids/tricyclic derivatives	
vitamin D in .....	1297	as .....	812
Cannabinergic system .....	1401	kynurenic acid derivatives as .....	810
as target for anti-inflammatory therapies .....	1401	pathophysiological roles of .....	810
effect on cell/experimental animal models .....	1404	quinazolin-2-ones/tricyclic derivatives as .....	817
effect on human immune system .....	1405	quinoxalin-2,3-diones/tricyclic derivatives as .....	814
Cannabinoid receptors .....	1403	Competitive glycine site antagonists .....	756
distribution of .....	1403	Computational methods .....	41
Carnitine/choline acyltransferases .....	48	to model/predict selectivity .....	41
CCR1 non-peptide ligands .....	1325		
CCR2 non-peptide ligands .....	1322		

Computational modeling .....	1609	7-Deazapurine 2'- <i>-</i> C-methylribonucleosides .....	885
of CYP1A2 .....	1610	synthesis of .....	885
of CYP2A6 .....	1610	7-Deazapurine -L-ribonucleosides .....	886
of CYP2C9 .....	1611	7-Deazapurine-pyrrolo[2,3- <i>d</i> ]pyrimidine-	
of CYP2D6 .....	1612	ribonucleoside .....	867
of CYP3A4 .....	1613	fusion reaction for .....	868
Crohn's disease (CD) .....	1710	metal salt procedure for .....	870
adalimumab in .....	1710	nucleobase anion glycosylation for .....	876
etanercept in .....	1710	nucleobase anion glycosylation under solid-	
infliximab in .....	1710	liquid conditions for .....	880
CRTH2 .....	1427	nucleobase anion glycosylation-sodium salt	
chemoattractant receptor-homologous		procedure for .....	877
molecule expressed on .....	1429	nucleobase anion glycosylation for .....	879
CXCR1 .....	1345	pyrrolo[2,3- <i>d</i> ]pyrimidine C-nucleosides for .....	883
antagonists of .....	1345	Schiff base procedure for .....	868
in treatment of inflammatory diseases .....	1345	silyl-hilbert-johnson reaction for .....	871,872
small molecule antagonists of .....	1345	synthesis of .....	867
CXCR2 .....	1345	Wittenburg procedure for .....	871
antagonists of .....	1345	Decision tree methods .....	31
in treatment of inflammatory diseases .....	1345	in pharmaceutical research .....	31
small molecule antagonists of .....	1345	Depression .....	1801
Cyclosporine .....	1774	mirtazepine/mianserin for .....	1808
anti-retroviral effects of .....	1774	selective serotonin reuptake inhibitors	
clinical studies of .....	1775	(SSRIs) for .....	1802
immunosuppressive effects of .....	1774	SERT inhibitors/5-HT <sub>1A</sub> antagonists for .....	1804
CYP2D6 .....	1620	SERT/NET/DAT inhibitors for .....	1804
early models of .....	1620	Dexoxadrol .....	723
models based on mammalian CYPS .....	1620	analogues of .....	723
Cysteine proteases .....	317,331	definitions of .....	723
caspase inhibitors for .....	318	molecular modeling of .....	730
cathepsin inhibitors for .....	320	NMDA receptor affinity of .....	723
3C-like protease (3CLpro) inhibitors for 321effect of		pharmacological evaluation of .....	724
aziridine-2,2-dicarboxylates/-2-car-		stability of .....	723
boxylates .....	340	stereochemistry of .....	723
effect of aziridines .....	334	structure of .....	723
effect of epoxides .....	333	structure-affinity-relationships of .....	726
effect of inhibitors containing activated double		synthesis of .....	723
bond .....	342	Dihydroartemisinin .....	521
effect of methylene ketones/esters .....	344	1,25-Dihydroxyvitamin D <sub>3</sub> .....	1273
effect of <i>N</i> -acylated aziridine-2,3-		A-ring modification of .....	1273
dicarboxylates .....	338	C2 substitution of .....	1274
effect of <i>N</i> -unsubstituted aziridine-2,3-dicarboxy-		Docking .....	52
lates .....	341	protein flexibility in .....	52
inhibitors of .....	331	Dopamine transporter .....	1825
parasitic cysteine protease inhibitors for .....	320	developments/therapeutic potential of .....	1825
Cytochrome P450 drug interactions .....	1619	effect of 1,4-dialkylpiperazines .....	1829
modeling studies of .....	1619	effect of 3-phenyltropanes .....	1826
Cytochrome P450 enzyme .....	1609	effect of benzotropines .....	1833
computational models for .....	1609	effect of phenylpiperidine derivatives .....	1832
predicting interactions with .....	1609	ligands for .....	1825
C-fluoroalkyl amino acids/peptides .....	1483	therapeutic potential for .....	1838
enzymatic resolution of .....	1483	uptake inhibitors of .....	1837
enzymatic resolution of .....	1488	Drug design .....	41,1473
fluoroalkyl groups on proteolytic stability of ...	1484	aromatic fluorine in .....	1473
interaction with enzymes .....	1483	computational approaches to .....	41
peptide coupling of .....	1483	3D-QSAR methods in .....	46
with peptides <i>via</i> enzymatic catalysis .....	1490	model ligand selectivity in .....	41

modeling protein structures in .....	51	in compound library preparation .....	222
role of chemogenomics .....	52	in database preparation .....	224
role of systems biology .....	52	in target determination/preparation .....	218
sequence analysis in .....	51	molecular docking of .....	226
technical considerations in .....	51	molecular interactions of .....	217
Drug discovery .....	245	Monte Carlo methods to .....	227
selective androgen receptor modulators in .....	245	rational design modulators of .....	221
Drug metabolism .....	500,1569,1579,1619	requirements for membrane localization of .....	237
<i>in silico</i> modeling of .....	1579	role in docking platforms .....	231
machine learning techniques for .....	1579	scoring functions of .....	228
modeling studies of .....	1619	structure based drug design of .....	218
quantitative structure activity relationships in ....	1569	Tabu methods for .....	228
Drug metabolism induction .....	1627	virtual screening of .....	217
aryl hydrocarbon receptor (AhR) in .....	1632	Estrogen-related receptors .....	203
constitutive androstane receptor (CAR) in .....	1630	biological functions of .....	207
farnesoid X receptor (FXR) in .....	1631	coactivators of .....	205
glucocorticoid receptor in .....	1634	crystal structures of .....	206
hepatocyte nuclear factor 4 in .....	1635	dimerization of .....	205
liver X receptor (LXR) in .....	1632	DNA-interacting sites of .....	204
molecular basis for nuclear receptor-		effect of 4-hydroxytoremifene .....	211
mediated .....	1628	effect of DES .....	211
PPAR in .....	1633	effect of phenolic acyl hydrazones GSK4716/ GSK9089 .....	210
prediction <i>in silico</i> .....	1627	effect of toxaphene/chlordane .....	211
pregnane X receptor (PXR) in .....	1629	effect of XCT790 .....	211
retinoid X receptor (RXR) in .....	1635	flavones in .....	210
Dutasteride .....	405,413	in cancer .....	208
as dual 5 $\alpha$ -reductase inhibitor .....	405	in energy metabolism .....	207
clinical development of .....	405	isoflavones in .....	210
clinical studies with .....	415	ligands of .....	210
discovery of .....	405,413	mediated modulation of estrogen	
EGFR .....	1690	responsiveness .....	207
biology of .....	1690	roles of .....	209
EMD 72000 .....	1699	serum components of .....	210
Endocannabinoid system .....	1401	structure of .....	203
Endogenous chemokine system .....	1319	transactivation potential of .....	205
receptor-ligand interactions in .....	1320	Etoxidrol .....	723
Ensemble approaches .....	36	analogues of .....	723
Epothilone .....	1537	definitions of .....	723
fluorinated analogues of .....	1537	molecular modeling of .....	730
ErbB family kinases .....	437	NMDA receptor affinity of .....	723
multiple kinase inhibition profile of .....	444	pharmacological evaluation of .....	724
potency/selectivity for .....	437	stability of .....	723
ERK pathway .....	1071	stereochemistry of .....	723
as target for cancer drug discovery .....	1071	structure of .....	723
Estrogen receptors .....	181,217	structure-affinity-relationships of .....	726
alternative binding pocket of .....	237	synthesis of .....	723
aromatase inhibitor resistance in .....	194	Excitatory amino acid transporters (EAATs) .....	836,1897
as therapeutic targets in breast cancer .....	181	expression of .....	1903
binding site of .....	219	ligands targeting .....	1897
biology of .....	182	Excitotoxicity .....	711
descriptor matching methods to .....	226	NMDA receptor-mediated .....	711
existence of membrane type .....	237	targeting PDZ domain proteins for treating .....	711
fragment based docking of .....	227	Extrasynaptic glu receptors .....	942
genetic algorithms of .....	227	activation of .....	942
		Finasteride .....	407
		as dual 5 $\alpha$ -reductase inhibitor .....	408

clinical efficacy of .....	408	guvacine analogues as .....	1868
pharmacokinetic/pharmacodynamic effects of .....	407	muscimol analogues as .....	1863
Fluorinated molecules .....	1457	nipecotic acid as .....	1865
as drug .....	1457	-proline analogues as .....	1869
based CNS drugs .....	1457	structure-activity relationships of .....	1861
in CNS imaging/diagnostics .....	1457,1458	THPO analogues as .....	1863
Fluorinated natural products .....	1529	uptake assays of .....	1862
clinical significance of .....	1529	GABA/Glu plasma membrane transporters .....	989
Fluorinated nucleosides .....	1499	across the plasma membrane .....	990
as antitumor agents .....	1499	in interplay of inhibitory/excitatory	
as antiviral .....	1499	neurotransmission .....	989
Fluorination .....	1447	Geldanamycin .....	1173
biochemical rationales of .....	1447	derivatives of .....	1173
in drug design/development .....	1447	Gemini .....	1250
Fluorine .....	1447,1529	Glial modulation .....	929
biodistribution of .....	1454	of GABAergic/glutamate ergic	
induced electronic perturbations of adjacent		neurotransmission .....	929
functionality .....	1449	Glutamate .....	929,941,949,961,989
intermolecular interactions of .....	1453	as modulator of embryonic/adult neurogenesis .....	949
isosteric replacements based on .....	1451	as modulator of neural precursor cell	
metabolic stability of analogues of .....	1451	proliferation and/or differentiation .....	952
substitution of .....	1448	in homeostasis .....	950
-Fluoro- / , -difluoro phosphonic acids .....	1466	inactivation of .....	930
in inhibitor design .....	1466	nonsynaptic receptors for .....	941
Focused library design .....	19	pharmacological aspects of .....	931
developments in .....	19	plasma membrane transporters of .....	989
ligand-based focusing in .....	22	receptor-induced signal transduction	
targeting gene-families in .....	19	downstream of calcium ion .....	963
GABA .....	929,935,941,969,975,989	receptors for .....	951
during pathological conditions <i>in vivo</i> .....	937	release of .....	930
extracellular level of .....	935	sources of .....	945
functional significance of co-localization of .....	969	spillover of .....	941
implications for epilepsy .....	975	synthesis/metabolism of .....	950
in hippocampal granule cells .....	975	transporters for .....	950
in nerve terminals .....	969	trophic effect of .....	961
<i>in vivo</i> microdialysis-HPLC measurements of .....	935	Glutamate binding proteins .....	823
inactivation of .....	931	selective ligands for .....	823
metabolism of .....	930	Glutamate receptor .....	823
nonsynaptic receptors for .....	941	desensitization of .....	828
origin/function of .....	936	partial agonism/antagonism of .....	829
pharmacological aspects of .....	931	Glutamate transport proteins .....	836
plasma membrane transporters of .....	989	Glutamate/aspartate analogs .....	1901
regulation of .....	936	conformationally constrained .....	1901
release of .....	931	Glutamic acid .....	1321
sources of .....	945	GluVII06 .....	1319
spillover of .....	941	for non-peptide ligands in chemokine	
transient spillover from synapse .....	944	receptors .....	1319
GABA transporter .....	1861	for small molecule ligands .....	1327
heterogeneity of .....	1861	molecular mechanism of action of .....	1328
GABA uptake inhibitors .....	1861	Glycine transporter type-1 (GlyT1) inhibitors .....	1883
ACHC analogues as .....	1870	chemistry of .....	1884
ACPC analogues as .....	1870	in GlyT1 mouse models .....	1893
acyclic GABA analogues as .....	1862	non-sarcosine-derived .....	1888
development of .....	1861	preparation of .....	1883
ecgonine analogues as .....	1868	sarcosine-derived .....	1884
<i>exo</i> -THPO analogues as .....	1864	testing of .....	1883

Glycine/NMDA receptor antagonist .....	651	NFAT (calcineurin) inhibitors for .....	1774
ACEA-1021 as .....	651	pharmacological modulation of immune	
as CNS therapeutic agents .....	651	activation in .....	1773
benzazepine derivatives as .....	655	T-cell activation pathways in .....	1770
quinolin-2(1 <i>H</i> )-ones derivatives as .....	654	Hsc70 modulators .....	1220
quinoxaline-2,3-dione derivatives as .....	652	identification of .....	1220
structure-activity relationship of .....	652	Hsp70 .....	1216
therapeutic applications of .....	656	action during replication of mammalian	
Granule cells .....	975	viruses .....	1219
GABAergic markers in .....	975	compensatory induction of .....	1218
Guanidines .....	81	in apoptosis .....	1216
		in cellular transformation .....	1216
		to reduces tumor immunogenicity .....	1218
		Hsp70 molecular chaperones .....	1215
Haematologic malignancies .....	1657	discovery of .....	1215
bexarotene in .....	1670	in inflammation .....	1220
bortezomib in .....	1673	in ischemia .....	1220
dab-IL-2 in .....	1670	mechanism of action of .....	1215
immunoregulatory drugs in .....	1657	roles in human disease .....	1215
immunotherapeutic drugs in .....	1657	to modulate protein conformational diseases .....	1219
monoclonal antibodies for .....	1657	Hsp90 .....	1173,1205
thalidomide in .....	1671	as novel target for cancer therapy .....	1205
Heat shock protein 90 (Hsp90) .....	1163	chimeric inhibitors of .....	1173
amino terminal nucleotide pocket in .....	1165	effect of geldanamycin .....	1173
as molecular target in cancer .....	1163	effect of radicicol .....	1173
inhibition of .....	1168	<i>N</i> -terminal ATP binding site of .....	1173
novobiocin binding to .....	1167	Hsp90 inhibitors .....	1183,1193
role of natural product inhibitors .....	1163	biological activities of .....	1187
Hepatitis B virus (HBV) .....	851	development of .....	1183,1193
acyclic nucleosides for .....	859	discovery of .....	1183,1193
adefovir/adefovir dipivoxil for .....	857	natural product based .....	1194
anti-HBV therapies against .....	852	purine-scaffold based .....	1183
entecavir for .....	858	pyrazole-scaffold based .....	1193
lamivudine for .....	854	synthesis of .....	1186
L-nucleosides for .....	860	targeting cancer by .....	1193
viral replication of .....	851	HSP90 molecular chaperone .....	1091
Heterotrporter .....	979	discovery of .....	1091
induced transmitter release .....	979	in cancer .....	1091
mediated release of glutamate from spinal cord		inhibitors of .....	1091
synaptosomes .....	980	natural product inhibitor of .....	1092
synaptosomes .....	980	synthetic inhibitors of .....	1099
High-throughput screening .....	19	5-HT receptors .....	1909
hybrid focusing approaches to .....	25	5-HT <sub>1A</sub> receptors .....	1997
hybrid techniques in .....	26	in pain treatment .....	1997
target-based focusing in .....	24	5-HT <sub>1A</sub> receptors .....	2029
using three-dimensional pharmacophores in .....	24	5-HT <sub>1R</sub> ligands .....	2005
Histamine H4 receptor .....	1365	pharmacophore models for .....	2005
clinical applications of .....	1369	5-HT <sub>2</sub> family .....	1910
discovery of ligands for .....	1366	5-HT <sub>2A</sub> receptors .....	1911,2029
in asthma .....	1370	5-HT <sub>2C</sub> receptors .....	1971
in cancer .....	1371	as targets for modulation of psychostimulant .....	1971
in inflammation .....	1369	based ligands for medicine/research .....	1977
in inflammatory bowel disease (IBD) .....	1370	distribution of .....	1973
in itch .....	1370	modulation of DA neurotransmission by .....	1973
in rheumatoid arthritis .....	1370	pharmacotherapy in humans .....	1977
role in anti-inflammatory therapy .....	1365	role in cocaine-evoked behaviors .....	1974
signaling pathways of .....	1366		
species variants of .....	1366		
HIV disease .....	1769		
immunosuppressive drugs in .....	1769		

structure/function of .....	1972	Inflammatory disease .....	151
use dependence of .....	1971	cannabinergic compounds in .....	1406
5-HT <sub>3</sub> receptor antagonists .....	2035	cannabinergic ligands in .....	1409
in rheumatic diseases .....	2035	therapeutic action of VIP PACAP in human/ animal models of .....	151
Human purinome .....	1129	Inflammatory disorders .....	113
structure-based drug design against .....	1129	2-alkylsulfanylimidazoles in .....	121
Human -secretase (BACE) inhibitors .....	569	small molecule inhibitors of p38 MAP kinase in .....	113
peptidomimetic BACE inhibitors as .....	573	treatment of .....	113
Hybrid methods .....	35	triaminotriazines in .....	138
 		Intracellular ceramide .....	1026
Ifenprodil .....	687	indirect action <i>via</i> mediation of .....	1026
evolution of pharmacophore related to .....	687	Ionotropic receptor .....	934
IGlur dysfunction .....	830	activation of .....	934
physiological implications of .....	830	Isothioureas .....	81
IGlur2 ligand binding domain .....	825	Isoxazoles .....	827
structure of .....	825	for glutamate receptor .....	827
Immune disease .....	156	 	
systemic versus local or targeted administration in .....	156	Kallikrein-kinin system .....	1353
Immunomodulatory agents .....	1335	K <sub>ATP</sub> channel openers .....	1031,1049
antagonists of CCR4 as .....	1335	benzopyrans as .....	1031
Immunoregulation .....	1765	cromakalim as .....	1049
Immunoregulatory drugs .....	1668	cyanoguanidines as .....	1037
mode of action of .....	1674	DHP-related structures as .....	1042
toxicity of .....	1674	diaminocyclobutenediones as .....	1041
Inducible nitric oxide synthase .....	77	from CRK benzopyran-based structure .....	1050,1052
competitive inhibitors of .....	84	structural classes of .....	1049
dimerization inhibitors of .....	85	structure-activity relationships of .....	1031
effect of compounds acting at flavin/calmodulin sites .....	84	synthetic chemistry of .....	1058
effect of compounds competitive with tetrahydrobiopterin .....	85	tertiary carbinols as .....	1043
for treatment of inflammatory diseases .....	77	thiadiazines as .....	1039
function of .....	77	thioformamides as .....	1038
inhibitors competitive with L-arginine at substrate-binding site .....	79	Kinesin motor proteins .....	1150
inhibitors of .....	79	structure of .....	1150
inhibitors of induction of .....	86	Kinin receptors .....	1353
selective inhibitors of .....	77	as therapeutic targets .....	1353
structure of .....	77	binding site homology modeling of .....	1358
Inflammation .....	94,103,1427	nonpeptide modulators of .....	1356
adhesion molecules in .....	96	non-selective ligands of .....	1358
antioxidants in .....	97	selective peptide modulators of .....	1354
C-reactive protein in .....	96	 	
CRTH2 for treatment of .....	1427	K <sub>v</sub> 7 channels .....	999
cytokines in .....	96	biophysical characteristics of .....	1000
fibrinogen in .....	96	brain regional distribution/organization of .....	1003
myeloperoxidase in .....	96	function of .....	999
oxidative stress in .....	97	in anxiety .....	1007
PGD <sub>2</sub> receptor agonists in .....	1430	in cognitive disorders .....	1008
PGD <sub>2</sub> receptor antagonists in .....	1431	in epilepsy .....	1006
prostanoid receptor (DP/DP <sub>1</sub> ) in .....	1429	in migraine .....	1007
role of nuclear receptors in inhibition of .....	103	in pain .....	1007
statins in .....	94	in stroke .....	1008
targeting prostaglandin D <sub>2</sub> receptors DP in .....	1427	<i>in-vivo</i> pharmacology of .....	1006
		modulator for .....	999,1009
		non-voltage dependent property of .....	1001
		open-state probability of .....	1001

pharmacology of .....	999	Metabotropic glutamate receptors .....	834
physiological regulation of .....	1001	Metallo-proteases .....	322
Lapatinib .....	435,452	anthrax lethal factor (LF) inhibitors for .....	324
as dual ErbB1/2 tyrosine kinase inhibitor .....	435	Botulinium neurotoxin serotype A (BoNTA)	
drug discovery of .....	435	for .....	324
for drug candidate selection .....	452	matrix metallo-protease inhibitors for .....	322
models of efficacy of .....	440	tetanus toxin C inhibitors for .....	326
pre-clinical data of .....	452	Miltefosine .....	543
<i>Leishmania</i> .....	539	mechanism of action of .....	543
drug resistance in .....	539	mechanism of resistance to .....	543
mechanisms of drug action in .....	539	Molecular description .....	4
Leishmaniasis .....	539	continuous-valued vector-based .....	6
chemotherapy of .....	539	graph-based .....	7
pentamidine for .....	542	sets-based .....	5
Leukemia cells .....	1270	Molecular descriptors .....	1599
C/EBP transcription factor in .....	1270	Molecular modeling .....	57
studies of cell cycle control in .....	1270	with whole toolkit .....	57
Leukocyte elastase .....	397	Monensin .....	173
Ligand-binding domain (LBD) .....	1229	Monoamine transporter substrates .....	1845
crystal structures of VDR based .....	1229	adverse effects of .....	1853
non genomic based .....	1236	ephedrine-related compounds as .....	1852
Linear glutamate/aspartate analogs .....	1897	mechanisms of .....	1846
		therapeutic potential of .....	1845
Malaria .....	479	Monoclonal antibodies .....	1687
treatment of .....	479	in management of solid tumors .....	1687
MAPK pathways .....	1267	limitations in .....	1689
signaling of monocytic differentiation by .....	1267	mechanisms of action of .....	1687
Matrix metalloproteinase inhibitors .....	289	trials with radioimmunotherapy in .....	1699
epigallocatechin gallate (EGCG) as .....	292	Monocytic differentiation .....	1267
flavonoids as .....	295	in human leukemia cells .....	1267
for prevention/treatment of cardiovascular/		role of MAPK pathways in .....	1267
neoplastic diseases .....	289	signaling of .....	1267
natural type .....	292	transcription factor activation in .....	1267
polyphenols as .....	294	Mossy fibers (MF) .....	975
synthetic type .....	295	Multidimensional molecular spaces .....	7
Matrix metalloproteinases (MMPs) .....	289	Multiple myeloma (MM) .....	1675
in cancer .....	289	Multiple objective methods .....	38
in cardiovascular disease .....	291	Mycophenolic mofetil .....	1775
in stroke .....	291	anti-retroviral effects of .....	1776
Medicinal chemistry space .....	3	clinical studies of .....	1776
basis of .....	3	immunosuppressive effects of .....	1775
cell-based selection in .....	10	mechanism of action of .....	1775
cluster-based selection in .....	9	NA inhibitors .....	429
compound selection in .....	8	based on 5-membered ring scaffolds .....	429
dissimilarity-based selection in .....	9	Natural products .....	1530
diversity in .....	3	Neural stem cell (NSC) .....	949
drug-likeness in .....	8	approaches to study .....	949
natural products/diversity-oriented synthesis in .....	11	Neuraminidase inhibitors .....	423
sources of diversity in .....	10	catalytic mechanism of .....	423
Memantine .....	677	development of .....	423
Metabolic disorders .....	203	discovery of .....	423
estrogen-related receptors as targets in .....	203	NA active site structure of .....	423

Neuregulins .....	672	polyamine site antagonists at .....	670
Neurodegeneration .....	613	regulation of apoptotic machinery in	
mice models of .....	613	protection by .....	795
Neuronal development .....	961	role of CA2 <sup>+</sup> /calmodulin dependent kinases	
glutamatergic influences in .....	961	in pro-survival signaling of .....	791
Neuropeptide mimetics/antagonists .....	151	role of ERK in pro-survival signaling of .....	792
in asthma .....	153	role of GSK3 inhibition in pro-survival	
in treatment of inflammatory disease .....	151	signaling of .....	793
PACAP as .....	151	role of P13K/AKT in pro-survival signaling of....	791
VIP as .....	151	role of trophic factors in mediated protection by...	794
Neurotrophic factors .....	965	structure of .....	663
induced by glutamate receptor stimulation .....	965	survival signaling pathways activated by .....	787
New molecular entities (NMEs) .....	461	NMDA/D1 receptor .....	801
approved by United States FDA .....	461	as target in drug development .....	801
biochemical mechanisms of .....	461	functional implications of .....	804
efficacy of .....	461	functional interactions of .....	802
safety of .....	461	NMDA-glycine antagonists .....	733
targeting non-human enzymes .....	471	aza-kynurenic acids as .....	733
NFAT .....	1772	<i>in vivo</i> .....	733
regulation of gene transcription by .....	1772	indole-2-carboxylic acids as .....	733
Nitric oxide (NO) .....	77	pharmacology of heterotricyclic based .....	734
NMDA ( <i>N</i> -methyl-D-aspartate receptor) .....	749,965	SM-18400 as .....	739
antagonists as potential pain therapeutics .....	749	SM-31900 as .....	741
in central sensitization .....	751	structure-activity relationships of .....	734
molecular structure of .....	749	synthesis of heterotricyclic based .....	739
non-competitive antagonists of .....	752	tricyclic azakynurenic acid as .....	741
physiological role of .....	750	tricyclic quinoxalinediones as .....	733
trophic effect of .....	965	Nociceptive processing .....	751
NMDA receptors .....	663,771,787,810	glutamate/glutamate receptor regulation in .....	751
antagonists for .....	668	Non-covalent cathepsin K inhibitors .....	355
channel blockers for .....	669	NR11 subfamily .....	1237
CREB as mediator of survival .....	793	NR LBD structures of .....	1237
dynamic regulation of .....	663	NR2B selective NMDA antagonists .....	687
effect of neuregulins .....	663	NR2B subtype-selective NMDA receptor antagonists ....	697
effect of transient cholesterol-rich membrane		development of .....	697
domains .....	663	NSC23766 .....	1112
embedded in complex functional networks .....	677	co-crystallization of .....	1115
function/physiology of .....	663,671	effect on cellular Rac activity/cell	
functional aspects of NR2 subunits of .....	672	transformation .....	1112
glycine site antagonists at .....	670	effect on Rac activity/hematopoietic stem cell	
homology-based model for glutamate binding		mobilization in animals .....	1113
site in .....	833	Nuclear receptors .....	471,1243,1627
hypofunction hypothesis for .....	772	dynamics of LBDs of .....	1245
in ALS .....	673	in metabolism induction .....	1629
in Alzheimer's disease .....	674	modeling studies of .....	1635
in depression .....	674	modulation of .....	245
in epilepsy .....	674	signaling of .....	1243
in excitotoxicity .....	673	Nucleoside analogs .....	851
in glutamate-signaling of .....	663	as anti-HBV agents .....	851
in multiple sclerosis .....	674	biological evaluation tools in developing .....	853
in pain .....	675	in clinical use .....	854
in Parkinson's disease .....	675	mechanism of action of .....	853
in schizophrenia .....	675	Nucleotides .....	894
in stroke .....	676		
in trauma .....	676		
ligands for .....	664		
mediated calcium toxicity .....	676		
pathophysiological roles of .....	810		

1,25(OH) <sub>2</sub> D <sub>3</sub> .....	1246	for 5-HT <sub>2</sub> R ligands .....	2012
molecular evaluation of analogues of .....	1247	for 5-HT <sub>4</sub> R ligands .....	2016
signaling of .....	1246	for 5-HT <sub>5</sub> R ligands .....	2018
Osteoporosis .....	355	for 5-HT <sub>6</sub> R ligands .....	2019
non-covalent cathepsin K inhibitors for .....	355	for 5-HT <sub>7</sub> R ligands .....	2020
treatment of .....	355	for metabotropic 5-HT receptor ligands .....	2005
p35/CDK5 .....	1269	Phosphonodifluoromethyl phenylalanine (F <sub>2</sub> Pmp) .....	1462
studies of .....	1269	design of .....	1465
P38 MAP kinase .....	113	phosphotyrosyl mimetic of .....	1465
allosteric <i>N,N'</i> -diarylurea based inhibitors of .....	139	preparation of .....	1467
diaryl heterocycle based inhibitors of .....	113	synthesis of .....	1465
non-diaryl heterocycle based inhibitors of .....	129	Phosphoryl moiety .....	1465
P38 MAP kinase inhibitors .....	142	in inhibitor design .....	1466
AMG-548 as .....	144	in pTyr-dependent processes .....	1465
BIRB-796 as .....	144	limitations of .....	1466
in clinical trails .....	142	Planar NEU5AC analogs .....	424
SCIO-469 as .....	142	based on cyclohexene scaffold .....	426
VX-702 as .....	142	based on dihydropyran scaffold .....	424
VX-745 as .....	144	Plasma kallikrein (PK) .....	1559
PACAP .....	152	Polyamine site/ifenprodil site antagonists .....	762
as pleiotropic modulators of immunity .....	152	Polygenic diseases .....	1791
development of receptor subtype specific		clinical targeting in .....	1795
agonists/antagonists .....	157	molecular target discovery for .....	1791
in animal inflammatory disease models .....	156	molecular target discovery paradigm for .....	1793
in asthma .....	153	target discovery in .....	1791
in autoimmune inflammatory diseases .....	154	Positron emission tomography (PET) .....	2027
in brain injury .....	155	clinical applications of .....	2028
in Crohn's disease .....	154	of major depression .....	2028
in multiple sclerosis .....	154	of serotonin reuptake sites .....	2031
in rheumatoid arthritis .....	154	Prostaglandin D <sub>2</sub> (PGD <sub>2</sub> ) .....	1427
in septic shock .....	152	chemoattractant receptor-homologous	
receptor agonists/antagonists of .....	156	molecule expressed on .....	1429
receptor analogs of .....	157	Protease inhibition .....	317
Pain .....	751,1997	structure/fragment-based approaches to .....	317
NMDA antagonists in models of .....	751	Protein kinases .....	46
use of antidepressants .....	1999	Protein-protein receptor oligomerization .....	803
use of opiates .....	1997	D1R/NMDAR interaction <i>via</i> .....	803
use of paracetamol .....	2000	Proteolytic enzyme inhibitors .....	1545
PAL-287 .....	1854	aspartic proteases as .....	1546
related agents of .....	1854	cysteine protease as .....	1559
Paromomycin .....	544	-fluoroalkyl ketones as .....	1545
mechanism of action of .....	544	(HCMV) as .....	1558
mechanism of resistance to .....	544	HIV protease (HIVp) as .....	1550
PDZ domains .....	712	human heart chymase (HHC) as .....	1557
effect of traditional Chinese herbs .....	716	human leukocyte elastase (HLE) as .....	1552
genetic mutations of .....	712	pepsin as .....	1546
human diseases by .....	712	peptidylfluoro-ketones as .....	1545
target interactions of .....	715	plasmepsin as .....	1549
Pentamidine .....	542	porcine pancreatic elastase/ -chymotrypsin as ..	1556
mechanism of action of .....	542	renin as .....	1548
resistance to .....	542	serine protease as .....	1551
Pharmacophore models .....	2005	Proteome mining .....	1122
for 5-HT <sub>1A</sub> .....	2005	principles of .....	1122
for 5-HT <sub>1B/1D</sub> .....	2011	PSD-95 .....	712
for 5-HT <sub>1E</sub> .....	2012	for NMDA receptor/nNOS signaling pathway .....	712



in conformational disease .....	168	central dopaminergic function of .....	1915
in defects of glycosylation .....	168	dihydrobenzofuran-containing structures for .....	1966
inhibitors of .....	168	distribution/circuitry in CNS .....	1914
Secretory pathway inhibitors .....	172	in depression .....	1916
in glycosylation .....	172	in Parkinson's disease .....	1918
in microtubule drugs .....	172	in schizophrenia .....	1917
Selective androgen receptor modulators (SARMs) .....	247	indole/indoline-containing structures for .....	1928
4-azasteroid derivatives as .....	261	pathology of .....	1909
carbonylaminobenzimidazoles as .....	260	physiology of .....	1909
4-cyano(nitro)aryl amines as .....	257	piperazine containing structure for .....	1953
in clinic .....	247	role in drug of abuse .....	1919
in male contraception .....	265	selective agents for .....	1927
in sarcopenia .....	264	tetracyclic containing structures for .....	1957
molecular classes of .....	247	Short interfering RNAs .....	913
<i>N</i> -aryl propionamides as .....	247	chemical modifications of .....	916
<i>N</i> -aryl succinimide/hydantoin derivatives as .....	255	chemical/structural diversity of .....	913
6-nitro(cyano)tetrahydroquinolines as .....	257	structural diversity of duplexes of .....	915
3-(2-nitrophenyl)thioindoles as .....	260	Single photon emission tomography (SPET) .....	2027
quinolone/coumarin derivatives as .....	251	clinical applications of .....	2028
therapeutic opportunities for .....	262	of major depression .....	2028
treatment of androgen deficiency in aging		of serotonin reuptake sites .....	2031
male (ADAM) by .....	263	Sitamaquine .....	545
treatment of BPH by .....	265	mechanism of action of .....	545
treatment of male hypogonadism by .....	262	mechanism of resistance to .....	545
treatment of sexual dysfunction by .....	266	Small interfering RNA .....	893,901
treatment/prevention of muscle wasting by .....	264	backbone modifications in .....	895
treatment/prevention of osteoporosis/		design of .....	902
osteopenia by .....	264	in cancer .....	906
use in women .....	266	in HIV/viral hepatitis .....	906
Self-splicing introns .....	1742	in SARS .....	906
Serine/threonine .....	1147	inducible type .....	907
Serine-proteases .....	48	libraries for .....	908
Serotonin .....	1987,2027	2'-OH modifications in .....	895
effect on spinal neurons .....	1989	plasmid-based expression of .....	903
in central nervous system .....	2027	production technologies to .....	902
in pain control .....	1987	RNA interference with chemically modified .....	894
in spinal cord .....	1988	terminal modifications in .....	896
PET/SPET molecular imaging of .....	2027	therapeutic potential of .....	906
radioligand for .....	2027	transcription of .....	903
receptors mediating spinal effects of .....	1991	viral vector delivery of .....	904
role in plastic changes in spinal cord .....	1993	Small ribozymes .....	1737
Serotonin (5-HT) <sub>2A</sub> receptor .....	1971	designing/testing of .....	1738
as targets for modulation of psychostimulant .....	1971	hairpin ribozyme as .....	1738
based ligands for medicine/research .....	1977	hammerhead ribozyme as .....	1737
distribution of .....	1973	therapeutical applications of .....	1740
modulation of DA neurotransmission by .....	1973	Solid tumors .....	1691
pharmacotherapy in humans .....	1977	cetuximab (C225) for .....	1691
role in cocaine-evoked behaviors .....	1974	chemotherapeutics for .....	1695
structure/function of .....	1972	combinations with novel molecules for .....	1696
use dependence of .....	1971	HER-2 for .....	1693
Serotonin reuptake inhibitors .....	1801	role of HER-2 in .....	1695
in treatment of depression .....	1801	Spinal sensory circuits .....	1987
medicinal chemistry of .....	1801	serotonergic modulation of .....	1987
Serotonin transporter .....	1802	Squamocin .....	1025
allosteric site on .....	1802	Steroid receptor .....	271
Serotonin <sub>2C</sub> (5-HT <sub>2C</sub> ) receptor .....	1909,1927	modulation of dose-response curve for .....	271
benzazepine derivatives for .....	1962	regulated gene expression of .....	271

Steroidal androgens .....	246	Tumorigenesis .....	1071
androgen therapies/limitations of .....	246	RAS-RAF-MEK-ERK pathway in .....	1071
Support vector machines .....	1593	Tumors .....	1206
difficulties of .....	1599	antiangiogenic agents against .....	1207
for <i>in silico</i> prediction of cytochrome P450		Hsp90 inhibitors for .....	1209
enzyme substrates/inhibitors .....	1593	treatment of .....	1206
liner classification of .....	1595	Tyrosine kinases .....	1147
nonlinear classification of .....	1597	VDR-agonists/antagonists .....	1273
performance of .....	1600	biological activity of .....	1273
properties of .....	1598	design of .....	1273
role in prediction of CYP3A4 inhibitors .....	1600	2,2-disubstituted analogue of .....	1280
Survival response .....	788	docking studies of .....	1277
mediated by NMDAR in developing nervous		modification at both C2/C10 positions .....	1278
system .....	788	synthesis of .....	1273
mediated by NMDAR to protect from neuronal		Vesicular glutamate transporter (GVT) .....	839
injuries .....	790	<i>Vinca</i> alkaloids .....	1534
subtypes of NMDAR mediate .....	791	fluorinated analogues of .....	1534
Synthetic vitamin D derivatives .....	1307	VIP .....	152
T helper 3 cells (TH3) .....	1761	as pleiotropic modulators of immunity .....	152
Tacrolimus .....	1774	development of receptor subtype specific	
anti-retroviral effects of .....	1774	agonists/antagonists .....	157
clinical studies of .....	1775	in animal inflammatory disease models .....	156
immunosuppressive effects of .....	1774	in asthma .....	153
Tau phosphorylation .....	583	in autoimmune inflammatory diseases .....	154
regulation of .....	583	in brain injury .....	155
Tau-pathies .....	580	in crohn's disease .....	154
animal models of .....	582	in multiple sclerosis .....	154
glycogen synthase kinase (GSK)-3 in .....	584	in rheumatoid arthritis .....	154
mechanisms of tau-mediated toxicity in .....	582	in septic shock .....	152
tau kinases in .....	583	receptor agonists/antagonists of .....	156
tau phoshpatases in .....	589	receptor analogs of .....	157
Taxol .....	1536	Vitamin D receptor .....	1243,1255,1267,1303
fluorinated analogues of .....	1536	agonistic/antagonistic ligands of .....	1243
Thermodynamics .....	1132	antagonists of .....	1249
of ligand binding .....	1132	20- <i>epi</i> agonists of .....	1247
Thrombin .....	1559	LBD crystal structure of .....	1246
TNF- .....	1707	ligand binding pocket of .....	1255
biological activities of .....	1707	ligand-mediated allosteric network of .....	1260
receptors for .....	1707	ligand recognition by .....	1255
Transcription factor .....	271	molecular understanding of .....	1243
Transient cholesterol-rich membrane domains .....	672	non-steroidal agonists of .....	1248
Trastuzumab .....	1693	related diseases .....	1303
in adjuvant setting .....	1696	superagonists of .....	1248
in neoadjuvant setting .....	1697	total alanine scanning mutational analysis of ....	1255
phase I trials of .....	1693	two-dimensional alanine scanning mutational	
phase II trials of .....	1693	analysis of .....	1258
phase III trials of .....	1694	Vitamin D receptor agonists .....	1297,1303
safety profile of .....	1697	effect on immune system .....	1297
Tryptase .....	394	in cancer .....	1297
targeting of .....	394	in drug discovery .....	1303
Tumor angiogenesis .....	1697	Vitamin D receptors .....	1229
		bound to superagonists ligands .....	1234
		crystal structures of .....	1233
		ligand binding domain of .....	1229

Zanamivir .....	425
Zevalin .....	1661
clinical trials of .....	1662
toxicity/safety of .....	1663